Zepp Health Q2 Revenue Rises 6.9% on New Wearables, Guides Q3 Above Consensus
ZEPP sits 17% above its 52-week low of $3.85.
Summary
Zepp Health reported Q2 revenue up 6.9% year-over-year, driven by new product launches (Active 3 Premium, Active Max, Cheetah). Gross margin improved to 37.4% on favorable product mix, but net loss widened due to FX headwinds and higher R&D/marketing spend. The company guided Q3 revenue to $68-73 million, above the prior Q2 guidance range, though supply constraints limited Bip and Helio Strap contribution. This follows the Q2 guidance issued in June; actual results and Q3 outlook provide new information for traders. Watch for whether supply issues ease and new product momentum continues into Q3.
At the time of this announcement, ZEPP was trading at $4.50 on NYSE in the Technology sector, with a market capitalization of approximately $70.8M. The 52-week trading range was $3.85 to $61.85. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.